Evidence map›Paper›PMID 19535594›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2009

Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models.

Matthew B Wilkinson, Guanghua Xiao, Arvind Kumar, Quincey LaPlant, William Renthal, Devanjan Sikder, Thomas J Kodadek, Eric J Nestler

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 1 synthesis or guideline pooled it, 262 citations in OpenAlex.

  1. Pooled it
  2. Nucleus accumbens neuron subtype translatome signatures in socially stressed females.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. The role of epigenetics in anxiety disorders.Molecular biology reports · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Matthew B WilkinsonFishberg Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029-6574, USA.
Guanghua Xiao
Arvind Kumar
Quincey LaPlant
William Renthal
Devanjan Sikder
Thomas J Kodadek
Eric J Nestler
The University of Texas Southwestern Medical Center · USIcahn School of Medicine at Mount Sinai · USManpower Demonstration Research Corporation · USSouthwestern Medical Center

Funding

Transgenic CoreP50MH066172 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI NESTLER, ERIC J. · 2002 to 2011
$19.4M
Using neuroeconomics to disentangle the transcriptional mechanisms underlying resilience versus susceptibility to stressR01MH051399 · NIMH · YALE UNIVERSITY · PI NESTLER, ERIC J. · 1994 to 2023
$10.2M
NIMH NIH HHS P50 MH066172NIMH NIH HHS R01 MH051399
6 · The paper itself

Abstract

Although it is a widely studied psychiatric syndrome, major depressive disorder remains a poorly understood illness, especially with regard to the disconnect between treatment initiation and the delayed onset of clinical improvement. We have recently validated chronic social defeat stress in mice as a model in which a depression-like phenotype is reversed by chronic, but not acute, antidepressant administration. Here, we use chromatin immunoprecipitation (ChIP)-chip assays--ChIP followed by genome wide promoter array analyses--to study the effects of chronic defeat stress on chromatin regulation in the mouse nucleus accumbens (NAc), a key brain reward region implicated in depression. Our results demonstrate that chronic defeat stress causes widespread and long-lasting changes in gene regulation, including alterations in repressive histone methylation and in phospho-CREB (cAMP response element-binding protein) binding, in the NAc. We then show similarities and differences in this regulation to that observed in another mouse model of depression, prolonged adult social isolation. In the social defeat model, we observed further that many of the stress-induced changes in gene expression are reversed by chronic imipramine treatment, and that resilient mice-those resistant to the deleterious effects of defeat stress-show patterns of chromatin regulation in the NAc that overlap dramatically with those seen with imipramine treatment. These findings provide new insight into the molecular basis of depression-like symptoms and the mechanisms by which antidepressants exert their delayed clinical efficacy. They also raise the novel idea that certain individuals resistant to stress may naturally mount antidepressant-like adaptations in response to chronic stress.

Indexed as

AnimalsAntidepressive Agents, TricyclicBehavior, AnimalChromatinChromatin ImmunoprecipitationCREB-Binding ProteinDepressionDisease Models, AnimalDominance-SubordinationGene ExpressionGenome-Wide Association StudyHistonesImipramineMaleMethylationMiceAntidepressive Agents, TricyclicChromatinCREB-Binding ProteinHistonesImipramine

Identifiers

PMID19535594
PMCPMC2717944
OpenAlexW2064804693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.